Welcome to our dedicated page for Ashland news (Ticker: ASH), a resource for investors and traders seeking the latest updates and insights on Ashland stock.
Ashland Inc. operates in the specialty chemicals sector, where news typically centers on earnings performance, operational adjustments, strategic transactions, and segment-level developments. For investors tracking ASH, this news page aggregates material announcements affecting the company's specialty chemicals business across pharmaceutical ingredients, personal care formulations, industrial additives, and coatings segments.
Chemical manufacturing companies generate distinct news patterns compared to other sectors. Quarterly earnings reports reveal segment performance trends, with particular attention to volume versus pricing dynamics that indicate market conditions. Production facility announcements signal capacity adjustments or operational changes affecting specific product lines. Executive leadership transitions can indicate strategic direction shifts, while dividend declarations reflect cash generation capabilities.
This news resource covers ASH-specific developments including facility operations updates, portfolio optimization moves, and business segment performance. Ashland's diversification across multiple end markets means news may involve pharmaceutical regulation impacts, construction market trends, personal care industry dynamics, or energy sector conditions. Material events filed with regulators appear here alongside earnings announcements, providing context for understanding how external factors affect specialty chemical demand.
Investors monitoring Ashland benefit from tracking operational announcements that signal production changes, strategic transactions that reshape the portfolio, and leadership changes that may alter company direction. The specialty chemicals sector involves complex supply chains, technical customer relationships, and application-specific product development, making company-specific news essential for understanding business trajectory beyond financial metrics alone.
Ashland Inc. (NYSE: ASH) reported Q4 fiscal 2024 financial results with sales of $522 million, up 1% year-over-year. Income from continuing operations was $19 million ($0.39 per diluted share), while adjusted EBITDA increased 68% to $124 million. The company faced challenges including HEC operating issues ($5 million impact) and softer coatings demand in China. Notable developments include the sale of nutraceuticals business to Turnspire Capital Partners and portfolio optimization initiatives that reduced overall sales by $24 million. The company repurchased 1.7 million shares and generated $88 million in ongoing free cash flow. For fiscal 2025, Ashland expects sales between $1.90-2.05 billion and adjusted EBITDA of $430-470 million.
Ashland Inc. (NYSE: ASH) has announced it will release its fourth-quarter fiscal 2024 earnings on Wednesday, November 6, 2024, at approximately 5 p.m. ET. The company will host a live webcast with securities analysts at 9 a.m. ET on Thursday, November 7, featuring an executive summary and detailed remarks. A slide presentation will be available in the Investor Relations section of the company's website. Key executives participating include Chair and CEO Guillermo Novo, CFO Kevin Willis, and other senior management team members. The webcast and supporting materials will be accessible through Ashland's website for 12 months after the event.
D.A. Davidson & Co. has acted as the exclusive financial advisor to Turnspire Capital Partners for an asset-backed credit facility to finance Turnspire's acquisition of Pharmachem Innovations, from Ashland Inc. (NYSE: ASH). Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services for the nutrition market. The company has approximately 500 employees across four production facilities in New Jersey, Utah, and Mexico. Ilya Koffman, Managing Partner at Turnspire, stated that the new capital structure will support Pharmachem's growth plans. This transaction showcases D.A. Davidson's capability in arranging financings for financial sponsors.
Ashland has commercialized easy-wet™ 300 n, a super wetting agent for crops including corn, soy, wheat, watermelon, and florals. This innovative product, developed using proprietary technology, offers superior wettability compared to non-silicone, non-ionic surfactants. Key features include:
- Biodegradable and silicone-free
- Reduces spray drift
- Effective at lower concentrations
- Improves pesticide adhesion to leaves
- Non-phytotoxic
The successful commercialization follows field trials and customer pilots, demonstrating Ashland's commitment to scaling high-performance, sustainable technologies. This product aligns with Ashland's strategy to balance crop yield improvement with sustainability goals.
Ashland Inc. (NYSE: ASH) has completed the sale of its nutraceuticals business to an affiliate of Turnspire Capital Partners on August 30, 2024. The transaction includes custom formulation and contract manufacturing capabilities for the nutrition market from production facilities in New Jersey, Utah, and Tamaulipas, Mexico. Financial terms were not disclosed.
Guillermo Novo, Ashland's CEO, acknowledged the strong portfolio and capabilities of the nutraceuticals business, thanking employees for their dedication. Ilya Koffman, managing partner at Turnspire, expressed enthusiasm for working with the newly named Pharmachem Innovations team to build on the business's legacy in the nutraceuticals space.
Citi served as financial advisor to Ashland, while Cravath, Swaine & Moore LLP acted as legal advisor for the transaction.
Turnspire Capital Partners has completed the acquisition of Pharmachem Innovations from Ashland Inc. (NYSE: ASH). Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services for the nutraceuticals industry. The company has approximately 500 employees across four production facilities in the US and Mexico.
As part of the acquisition, Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers as Interim CEO. Both executives bring significant experience in private equity-owned businesses and the nutraceuticals sector. Turnspire aims to leverage its expertise in transforming corporate carve-outs to capitalize on growth opportunities in Pharmachem's markets.
Pharmachem Innovations, has launched as an independent company following its acquisition from Ashland, Inc. (NYSE: ASH) by Turnspire Capital Partners The company, headquartered in Kearny, NJ, is a leading provider of nutraceuticals products and solutions with manufacturing facilities in the US and Mexico.
Maurice Murphy has been named Executive Chairman, while Jeff Rogers joins as Interim CEO. Pharmachem aims to accelerate growth through customer partnerships and investments in new capabilities. The company produces proprietary and private-labeled products for various health applications and offers custom formulation and contract manufacturing services.
Ashland Inc. (NYSE: ASH) has announced a quarterly cash dividend of $0.405 per share on its common stock. The dividend will be paid on September 15, 2024, to stockholders of record as of September 1, 2024. As of July 31, 2024, Ashland had 48,832,846 outstanding shares of common stock. This decision by the board of directors demonstrates the company's commitment to returning value to shareholders and may indicate confidence in Ashland's financial stability and future prospects.
Ashland (NYSE: ASH) reported Q3 2024 financial results, ending June 30. Sales reached $544 million, slightly down from $546 million YoY. Net income plummeted to $6 million, or $0.12 per share, compared to $50 million the previous year. Income from continuing operations was $31 million, down from $42 million, while adjusted income excluding intangibles amortization was $75 million, up from $65 million. Adjusted EBITDA grew 5% to $139 million.
Cash flows from operating activities totaled $128 million, with free cash flow at $112 million. The company repurchased 1.3 million shares, leaving $770 million in buyback authorization. Ashland predicts Q4 sales of $530-$540 million and full-year guidance at $2.1 billion in sales and $465-$475 million in adjusted EBITDA.
Segments saw mixed performance: Life Sciences sales dropped 11%, Personal Care rose 20%, Specialty Additives decreased 1%, and Intermediates fell 16%. The company's optimization initiatives are expected to impact future revenue and operations.
Ashland Inc. (NYSE: ASH) has announced its schedule for the fiscal 2024 third-quarter earnings release and conference call webcast. The earnings release will be issued on Tuesday, August 6, 2024, at approximately 5 p.m. ET. The live webcast with securities analysts will take place on Wednesday, August 7, at 10 a.m. ET.
Key participants in the webcast presentation include Guillermo Novo (Chair and CEO), Kevin Willis (SVP and CFO), and William Whitaker (VP Finance and Director of Investor Relations). A slide presentation will be available in the Investor Relations section of Ashland's website. The webcast and supporting materials will be accessible for 12 months after the live event.
FAQ
What is the current stock price of Ashland (ASH)?
What is the market cap of Ashland (ASH)?
